SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors were originally developed for optimizing glycemic control in Type 2 diabetes mellitus (T2DM) and have since gained recognition for their cardiorenal benefits in both diabetic and nondiabetic populations [1].